Or­p­hazyme's pipeline-in-a-prod­uct whiffs in sec­ond tri­al, though FDA de­ci­sion still awaits

Or­p­hazyme’s cen­tral mol­e­cule has whiffed in its sec­ond ma­jor test.

The Dan­ish biotech an­nounced Mon­day that ari­mo­clo­mol, their “pipeline-in-a-prod­uct” mol­e­cule, failed in a Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER